Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 944-950

  Schuler, U S ^a   Renner, U D ^a   Kroschinsky, F ^a   Johne, C ^a   Jenke, A ^a   Naumann, R ^a   Bornhauser M ^a   Deeg, H J ^a   Ehninger, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

HSCT; Intravenous busulphan; Pharmacokinetics

Indexed keywords

BENZODIAZEPINE; BUSULFAN; CYCLOSPORIN A; DIMETHYL SULFOXIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TOLERANCE; FEMALE; GRAFT FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VEIN OCCLUSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AREA UNDER CURVE; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; LYMPHOMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034791846     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03044.x     Document Type: Article

References (21)

1. Acute safety and pharmacokinetics of intravenous busulphan when used with oral busulphan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
2. Busulphan pharmacokinetics do not predict relapse in acute myeloid leukemia
3. Formulation and stability of busulphan for intravenous administration in high-dose chemotherapy
4. Quantitation of busulphan in plasma by high-performance liquid chromatography using postcolumn photolysis
5. Myeloablation by intravenous busulphan and hematopoietic reconstitution with autologous marrow in a canine model
6. Plasma concentrations and pharmacokinetics of dimethylsulphoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants
7. Use of a water-soluble busulphan formulation - Pharmacokinetic studies in a canine model
8. Pharmacokinetics of busulphan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
9. Pharmacokinetic and metabolic studies of high-dose busulphan in adults
10. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
11. Busulphan bioavailability
12. Pharmacokinetics and distribution of liposomal busulphan in the rat: A new formulation for intravenous administration
13. Busulphan concentration in relation to permanent alopecia in recipients of bone marrow transplants
14. A phase I/II study of multiple-dose intravenous busulphan as myeloablation prior to stem cell transplantation
15. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulphan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
16. Busulphan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted?
17. Pharmacokinetics of intravenous busulphan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation
18. Busulphan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia
19. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulphan levels on the outcome of transplantation
20. Graft-rejection and toxicity following bone marrow transplantation in relation to busulphan pharmacokinetics